Recursion Pharmaceuticals Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Recursion Pharmaceuticals, Inc. (RXRX) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-463.66-328.07-239.48-186.48-87.01
Depreciation & Amortization36.4924.4011.768.413.94
Stock Based Compensation81.6953.5027.9114.844.29
Change in Working Capital-38.00-50.26111.51-0.3130.83
Change in Accounts Receivable-6.07-7.760.00-5.38-1.12
Change in Accounts Payable6.44-0.991.771.75-0.19
Change in Other Working Capital-10.3311.458.564.105.47
Other Operating Activities24.2011.4524.964.101.66
Net Cash from Operating Activities-359.17-287.78-83.52-158.61-45.40
Investing Activities
Capital Expenditures-13.70-12.5537.36-39.80-5.83
Acquisitions277.101.840.000.00-2.60
Purchases of Investments0.000.48230.61-301.140.00
Sales/Maturities of Investments-3.350.48230.6169.19-0.90
Other Investing Activities-3.350.000.000.000.60
Net Cash from Investing Activities260.06-10.23193.25-271.74-8.74
Financing Activities
Debt Repayment-4.44-0.77-0.09-12.800.00
Common Stock Issued308.56128.09143.71462.900.68
Other Financing Activities8.140.000.000.000.00
Net Cash from Financing Activities304.12140.13154.35458.54246.14
Summary
Effect of Forex Changes on Cash-3.410.19-0.310.000.00
Net Change in Cash201.60-157.88264.0728.18192.00
Cash at Beginning of Period401.43559.11295.35267.170.00
Cash at End of Period603.02401.43559.11295.350.00
Free Cash Flow-372.87-300.33-120.88-198.41-51.23
Supplemental Disclosures
Interest Paid0.000.000.060.680.99